Timothy Beukelman, MD, MSCE
Associate Professor of Medicine
Division of Pediatric Rheumatology
University of Alabama at Birmingham
Heather Benham, DNP, RN, CPNP
Ambulatory Care - Pediatric Rheumatology
Texas Scottish Rite Hospital for Children
CME: 0.75 AMA PRA Category 1 CreditTM
NAPNAP CE: 0.75 contact hour (0.25 of which contains pharmacology content)
Juvenile idiopathic arthritis (JIA) is the most common chronic inflammatory arthritis in the pediatric population, affecting over 300,000 children and adolescents in the United States. The management of JIA represents a significant challenge to physicians, NPs, and other clinicians, particularly those in front-line specialties such as pediatrics and primary care. This activity will address timely diagnosis/classification of JIA and appropriate treatment, which are critical for preventing joint damage and improving long-term outcomes.
This activity is jointly provided by the National Association of Pediatric Nurse Practitioners, Penn State College of Medicine, and MCM Education.
This activity is designed for pediatricians, pediatric NPs, and other clinicians who encounter/manage JIA in pediatric patients.
Upon completion of this educational activity, the participant should be able to:
- Recognize the clinical signs and symptoms of JIA and JIA subtypes.
- Select appropriate imaging and laboratory studies to diagnose JIA.
- Summarize the characteristics and efficacy of pharmacologic agents used to manage JIA and those in late-stage development.
- Discuss the side effects of pharmacologic agents used to manage JIA and those in late-stage development.
Timothy Beukelman, MD, MSCE, discloses that he has served as a consultant for UCB, Novartis, Sobi, and Bristol-Myers Squibb.
Heather Benham, DNP, RN, CPNP, has nothing to disclose.
Penn State faculty and staff involved in the development and review of this activity have nothing to disclose.
Lilian McVey, MD, medical writer, has nothing to disclose.
Kathleen Hines, MCM Education VP, Editorial Affairs, has nothing to disclose.
Terry Ann Glauser, MD, MPH, MCM Education VP, Medical Affairs, has nothing to disclose.
It is the policy of the National Association of Pediatric Nurse Practitioners and Penn State College of Medicine to ensure balance, independence, objectivity and scientific rigor in all of their educational activities including those which are sponsored and cosponsored. All faculty are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation. The intent of this disclosure is not to prevent a presenter with significant financial interest or other relationship from making the presentation, but rather to provide the audience with information with which they can make their own judgments. It remains for the audience to determine whether the speaker's interests or relationships may influence the presentation with regard to exposition or conclusion. Faculty are also expected to openly disclose any off-label, experimental, or investigational use of drugs or devices in their presentations.
Please consult full prescribing information before using any product mentioned in this activity. If using products in an investigational, off-label manner, it is the responsibility of the prescribing clinician to monitor the medical literature to determine recommended dosages and uses of the drugs. Neither the publisher nor the providers promote the use of any agent outside of approved labeling.
This program is accredited for 0.75 NAPNAP CE contact hours (0.25 of which contains pharmacology content) per the National Association of Pediatric Nurse Practitioners Continuing Education Guidelines.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and MCM Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Penn State College of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Credit is awarded to participants who score 80% or better on the post-test.
The online activity will take approximately 45 minutes to complete.
For questions regarding CME credit, contact Penn State Continuing Education at (717) 531-6483 or ContinuingEd@hmc.psu.edu. Please reference activity code G6335-19-T.
Commercial Support Statements
Supported by educational grants from Novartis Pharmaceuticals Corporation and AbbVie.
Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers
- Please turn off all pop-up blockers to allow access to the educational activity.
- Click on the "Start program" icon at the bottom of this page. If you are not already registered as a user of this website, this will bring you to the login/registration page where you will be able to register as a new CMEcorner.com member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
- The next screen will permit you to check for or download the Flash player required to run this program and to begin the program presentation. The activity will take approximately 45 minutes to complete.
- After you have finished reviewing the activity, click on the "Post-test" button.
- Instructions for completing and submitting the post-test and evaluation are provided on the post-test screen.
©2018, MCM Education. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, the National Association of Pediatric Nurse Practitioners, Penn State College of Medicine, Novartis Pharmaceuticals Corporation, or AbbVie. Any medications, diagnostic procedures, or treatments discussed by the faculty should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.